Weekend News: Business, Finance and Innovations in Biotech and Pharma Industries
After the relaxing weekend we are back again with some latest news that has happened while we were away. Check it out here;
EC approved Novartis’ Revolade for pediatric ITP
Novartis’ (Basel, Switzerland) Revolade which belongs to class of thrombopoietin receptor agonists got approved by European Commission for treatment of pediatric patients (aged 1 or above) suffering from chronic immune thrombocytopenic purpura (ITP). Revolade got approved as tablet as well as oral suspension formulation. The drug is already approved in Europe for adults.
ITP is a rare blood disorder in which the patient suffers from low platelet count having normal bone marrow without the other symptoms of thrombocytopenia.
BioSilta entered licence agreement to make EnPresso-CyDisCo expression technology
BioSilta Ltd (Cambridge, UK ) entered in the licence agreement for worldwide exclusive rights to CyDisCo (Cytoplasmic Disulphide bond formation in E. coli) protein production technology from the University of Oulu (Finland). Under this agreement, BioSilta will combine their proprietary EnPresso culture systems technology with CyDisCo protein production technology to make EnPresso-CyDisCo expression systems to be available to scientists and bio-processing engineers for production of difficult to produce proteins. The technology can also furnish a system for delivery of proteins in higher yield and quality. It can also be used for enhancing the production of various other proteins containing multiple disulphide bonds like hormones and bioactive peptides.
MedDay raised $38.7M for phase III trial of its multiple sclerosis candidate
MedDay Pharmaceuticals (Paris, France) raised $38.7 million as a series B funding for the late stage clinical trial of its lead multiple sclerosis candidate-MD1003. The series B round was lead by the fresh investors Edmond de Rothschild Investment Partners. Other than this other participants were the InnoBio, Sofinnova Partners and Large Venture funds of Bpifrance.